Financial Results for Quarter and Year ended on March 31, 2026

Emphasis Of MatterPat Growth 25pctExceptional ItemAuditor Mid Year ChangeContingent Liabilities IncreasedDebt Equity ThresholdResults View source PDF

KRSNAA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.8%1-day move

₹550.00

prior close

₹622.55

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-7.9-9.7-8.8-8.4-1.8+0.0-1.7-0.5-1.7+0.5-2.5-1.8-1.4—

Up moveDown movePending

AI summary

Krsnaa Diagnostics reported audited standalone PAT of INR 1,026.75 million (FY26) vs INR 828.08 million (FY25), a growth of ~24%. Consolidated PAT grew stronger at INR 1,014.31 million vs INR 776.08 million, a ~30.7% increase. Standalone revenue from operations was INR 6,909.47 million (up 1.4% YoY) while consolidated revenue was INR 7,727.74 million (up 7.8%). The company recognized a one-time exceptional gain of INR 258.75 million from fair valuation of retained investment after ceasing significant influence over associate Apulki Healthcare. Finance costs increased significantly to INR 339.41 million (standalone) due to higher borrowings. Non-current borrowings surged to INR 4,371.44 million from INR 185.04 million, largely due to debenture issuance. The board recommended a final dividend of INR 2 per share (40% face value).

Likely market impact

Strong PAT growth driven by exceptional gain and operational improvement. The massive increase in borrowings raises leverage concerns. Pending tax demand of INR 626.90 million and proposed auditor change require monitoring.